Abcam, ab204367, Anti-SGF29 antibody - N-terminal

Size: 100µL
Rabbit Polyclonal SGF29 antibody. N-terminal. Suitable for IHC-P, ICC/IF and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human SGF29 aa 1-100.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human SGF29 aa 1-100. The exact immunogen used to generate this antibody is proprietary information.Q96ES7

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.2Preservative: 0.02% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SGF29 also known as SAGA-associated factor 29 is a component of the SAGA (Spt-Ada-GCN5 acetyltransferase) coactivator complex which is responsible for transcriptional regulation. The SGF29 protein has a molecular mass of approximately 60 kDa. Researchers have observed its expression in various tissues though it is more prominent in the nucleus where it exerts its functional roles. SGF29 interacts with histone H3 and recognizes the H3K4me3 mark which plays an important role in recruiting other SAGA components for transcription activation.
Biological function summary
The role of SGF29 involves it in chromatin remodeling and transcriptional activation processes. It acts as a scaffold protein binding to methylated histone H3 lysine residues and helps localize the SAGA complex to chromatin sites that are marked for transcription. By attaching to these regions SGF29 facilitates the acetylation of histones a modification that leads to the relaxation of chromatin structure more accessible to transcription machinery.
Pathways
Researchers describe SGF29 as part of the transcriptional regulation pathway and epigenetic modification processes. SGF29 is especially significant in pathways involving the acetylation of histones through the SAGA complex. It works closely with other proteins such as GCN5 and ADA2 which are also components of the SAGA complex. SGF29's interaction with these proteins ensures that acetylation proceeds efficiently influencing gene expression patterns.
SGF29 implications are evident in some cancer types and specific neurodevelopmental disorders. Scientists noticed that aberrant expression or mutations in SGF29 can correlate with tumorigenesis due to misregulated transcription processes. Additionally certain neurodevelopmental disorders can arise when there are disruptions in the pathways SGF29 is involved with potentially affecting cognitive function. These disorders sometimes link SGF29’s abnormal activity with misregulated histone modifications and the modulation of genes associated with neuronal development.